EDITAS MEDICINE, INC. Restructuring Charges
EDITAS MEDICINE, INC. (EDIT) reported Restructuring Charges of $79.17 million for the 7-month period ending 2025-06-30, per its 10-Q filed 2025-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:RestructuringCharges · last filed 2025-08-12
- EDITAS MEDICINE, INC. restructuring charges for fiscal 2024 was $12.23M.
- EDITAS MEDICINE, INC. restructuring charges for fiscal 2023 was $0.00.
- EDITAS MEDICINE, INC. restructuring charges for fiscal 2022 was $0.00.
| Period end | Restructuring Charges 4 month | Restructuring Charges 7 month | Restructuring Charges 12 month |
|---|---|---|---|
| 2025-06-30 | $79.17M 10-Q · filed 2025-08-12 | ||
| 2025-03-31 | $53.09M 10-Q · filed 2025-05-12 | ||
| 2024-12-31 | $12.23M 10-K · filed 2025-03-05 | ||
| 2023-12-31 | $0.00 10-K · filed 2025-03-05 | ||
| 2022-12-31 | $0.00 10-K · filed 2025-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |